Kanagawa, Japan

Masahiro Oshima

This inventor holds 1 USPTO granted patent. Top assignee: Mitsubishi Chemical Corporation. Active years: 2001.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Masahiro Oshima. Retrieved from https://idiyas.com/inventor/masahiro-oshima-hh44kmnm

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2001

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Masahiro Oshima: Innovator in Anticoagulant Compounds

Introduction

Masahiro Oshima is a notable inventor based in Kanagawa, Japan. He has made significant contributions to the field of medicinal chemistry, particularly in the development of anticoagulant compounds. His work has implications for the treatment of various medical conditions related to blood coagulation.

Latest Patents

Oshima holds a patent for "Penicillaminamide derivatives," which are compounds represented by a specific general formula. These compounds exhibit potent inhibitory activity against thrombin, making them useful as anticoagulants. The patent details various structural components, including alkyl groups and amino groups, which contribute to the compounds' effectiveness.

Career Highlights

Masahiro Oshima is associated with Mitsubishi Chemical Corporation, where he has been involved in innovative research and development. His work has led to advancements in the pharmaceutical industry, particularly in creating new therapeutic agents.

Collaborations

Oshima has collaborated with notable colleagues, including Norimichi Iwase and Misao Okitsu. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Masahiro Oshima's contributions to the field of anticoagulant compounds highlight his innovative spirit and dedication to advancing medical science. His work continues to impact the pharmaceutical industry positively.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…